Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Txinno Bioscience Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is the only one currently pending for the company. It is assigned to 1 distinct examiner and a single art unit. This lack of distribution means the company's current prosecution is highly concentrated.
HASTINGS, ALISON AZAR is the busiest examiner for this portfolio. This individual is responsible for the 1 pending office action. Because the entire workload is handled by this one person, the company's success in this technology area depends on a single relationship. There are no other examiners or art units to provide a comparison for the current prosecution strategy.
A practitioner must tailor their approach specifically to HASTINGS, ALISON AZAR. The 1 pending office action requires a deep understanding of this examiner's specific tendencies. Since the case is in a single art unit, the practitioner should also focus on the specific guidelines of that unit. The absence of other pending cases means there is no opportunity to test different arguments across multiple examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920992 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17920992 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | — | Pending | Oct 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTxinno Bioscience Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alison Azar Hastings has the most, with 1 of Txinno Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
